Skip to Main content Skip to Navigation

Implications de la protéine DYRK1A dans la pathologie Alzheimer et développement de stratégies thérapeutiques

Abstract : Current view conceptualizes Alzheimer’s disease (AD) as a continuum, with dementia representing the clinical outcome of a long period of cumulative pathological events in the brain of individual with free cognitive symptoms. New therapies for AD should ideally be started before the onset of symptoms but the lack of suitable tools mimicking preclinical stage of AD limits their future evaluations. In this work, we break this technological limitation. A new animal model have been developed in which a small amount of soluble Aβs forms able to induce hyper-phosphorylation of Tau is sufficient to disturb cognitive function long before classical lesions occur (amyloid plaques, neurofibrillary tangles and inflammation). This technological breakthrough allows us to evaluate involvement of the protein kinase DYRK1A and therapeutic potential of molecules modifying its functions in different stages of AD. Our results demonstrate that inhibition of its kinase activity reduces hyper-phosphorylation of Tau proteins and alleviates memory function in our preclinical AD-like animal model. In contrast, we provide evidences that DYRK1A undergoes a cleavage in brain of patient with clinical AD and gains new biological functions. Prevention of this proteolysis reduces inflammation and restores cognitive impairments in a clinical AD-like mice model. By targeting distinct phases of the disease, these data open avenue for personalized medicine and more-targeted treatment strategies.
Complete list of metadatas

Cited literature [462 references]  Display  Hide  Download
Contributor : Abes Star :  Contact
Submitted on : Wednesday, October 2, 2019 - 1:05:42 AM
Last modification on : Friday, October 23, 2020 - 4:52:08 PM


Version validated by the jury (STAR)


  • HAL Id : tel-02303038, version 1



Benoit Souchet. Implications de la protéine DYRK1A dans la pathologie Alzheimer et développement de stratégies thérapeutiques. Neurobiologie. Université Paris Saclay (COmUE), 2018. Français. ⟨NNT : 2018SACLS346⟩. ⟨tel-02303038⟩



Record views


Files downloads